Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422877 · ClinicalTrials.gov registry record · Phase 2
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
A Phase 2 study, sponsored by American Regent.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00422877 is a Phase 2 study that was terminated before completion, run by American Regent. The registered enrollment target is 13 participants.
The verdict
NCT00422877, a Phase 2 study, was terminated before completion, sponsored by American Regent.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with primary liver cancer being treated with weekly Taxoprexin® Injection. To explore the trough and peak blood levels of Taxoprexin® and paclitaxel in these patients.
Interventions
- DRUG Taxoprexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422877
The ClinicalTrials.gov registry entry for NCT00422877 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Taxoprexin is the first listed.
NCT00422877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422877 about?
NCT00422877 is a clinical study titled "Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract". To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment fail...
What is the current status of trial NCT00422877?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2007-01. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00422877?
The interventions under investigation include: Taxoprexin (DRUG).
Who is sponsoring clinical trial NCT00422877?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.